Timothy Sterling
Last active: 3/14/2018

Profile

None provided

Publications

The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Recent Abacavir Use Increases Risk of Type 1 and Type 2 Myocardial Infarctions Among Adults With HIV. Elion RA, Althoff KN, Zhang J, Moore RD, Gange SJ, Kitahata MM, Crane HM, Drozd DR, Stein JH, Klein MB, Eron JJ, Silverberg MJ, Mathews WC, Justice AC, Sterling TR, Rabkin CS, Mayor AM, Klein DB, Horberg MA, Bosch RJ, Eyawo O, Palella FJ, North American AIDS Cohort Collaboration on Research and Design of IeDEA (2018) J Acquir Immune Defic Syndr 78(1): 62-72
    › Primary publication · 29419568 (PubMed) · PMC5889316 (PubMed Central)
  2. Exposure to Latent Tuberculosis Treatment during Pregnancy. The PREVENT TB and the iAdhere Trials. Moro RN, Scott NA, Vernon A, Tepper NK, Goldberg SV, Schwartzman K, Leung CC, Schluger NW, Belknap RW, Chaisson RE, Narita M, Machado ES, Lopez M, Sanchez J, Villarino ME, Sterling TR (2018) Ann Am Thorac Soc 15(5): 570-580
    › Primary publication · 29393655 (PubMed) · PMC6624829 (PubMed Central)
  3. Increased non-AIDS mortality among persons with AIDS-defining events after antiretroviral therapy initiation. Pettit AC, Giganti MJ, Ingle SM, May MT, Shepherd BE, Gill MJ, Fätkenheuer G, Abgrall S, Saag MS, Del Amo J, Justice AC, Miro JM, Cavasinni M, Dabis F, Monforte AD, Reiss P, Guest J, Moore D, Shepherd L, Obel N, Crane HM, Smith C, Teira R, Zangerle R, Sterne JA, Sterling TR, Antiretroviral Therapy Cohort Collaboration (ART-CC) investigators (2018) J Int AIDS Soc 21(1)
    › Primary publication · 29334197 (PubMed) · PMC5810321 (PubMed Central)
  4. The Relationship Between Latent Tuberculosis Infection and Acute Myocardial Infarction. Huaman MA, Ticona E, Miranda G, Kryscio RJ, Mugruza R, Aranda E, Rondan PL, Henson D, Ticona C, Sterling TR, Fichtenbaum CJ, Garvy BA (2018) Clin Infect Dis 66(6): 886-892
    › Primary publication · 29069328 (PubMed) · PMC5850031 (PubMed Central)
  5. Cancer-Attributable Mortality Among People With Treated Human Immunodeficiency Virus Infection in North America. Engels EA, Yanik EL, Wheeler W, Gill MJ, Shiels MS, Dubrow R, Althoff KN, Silverberg MJ, Brooks JT, Kitahata MM, Goedert JJ, Grover S, Mayor AM, Moore RD, Park LS, Rachlis A, Sigel K, Sterling TR, Thorne JE, Pfeiffer RM, North American AIDS Cohort Collaboration on Research and Design of the International Epidemiologic Databases to Evaluate AIDS, North American AIDS Cohort Collaboration on Research and Design of the International Epidemiologic Databases to Evaluate AIDS (2017) Clin Infect Dis 65(4): 636-643
    › Primary publication · 29017269 (PubMed) · PMC5849088 (PubMed Central)
  6. CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus-Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC). Trickey A, May MT, Schommers P, Tate J, Ingle SM, Guest JL, Gill MJ, Zangerle R, Saag M, Reiss P, Monforte AD, Johnson M, Lima VD, Sterling TR, Cavassini M, Wittkop L, Costagliola D, Sterne JAC, Antiretroviral Therapy Cohort Collaboration (ART-CC) (2017) Clin Infect Dis 65(6): 959-966
    › Primary publication · 28903507 (PubMed) · PMC5850630 (PubMed Central)
  7. Tuberculosis Meningitis. Bourgi K, Fiske C, Sterling TR (2017) Curr Infect Dis Rep 19(11): 39
    › Primary publication · 28895024 (PubMed)
  8. Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor-Based Regimens. Norwood J, Turner M, Bofill C, Rebeiro P, Shepherd B, Bebawy S, Hulgan T, Raffanti S, Haas DW, Sterling TR, Koethe JR (2017) J Acquir Immune Defic Syndr 76(5): 527-531
    › Primary publication · 28825943 (PubMed) · PMC5680113 (PubMed Central)
  9. Outcomes of HIV-positive patients with cryptococcal meningitis in the Americas. Crabtree Ramírez B, Caro Vega Y, Shepherd BE, Le C, Turner M, Frola C, Grinsztejn B, Cortes C, Padgett D, Sterling TR, McGowan CC, Person A (2017) Int J Infect Dis : 57-63
    › Primary publication · 28807740 (PubMed) · PMC5649441 (PubMed Central)
  10. Increased Risk of Myocardial Infarction in HIV-Infected Individuals in North America Compared With the General Population. Drozd DR, Kitahata MM, Althoff KN, Zhang J, Gange SJ, Napravnik S, Burkholder GA, Mathews WC, Silverberg MJ, Sterling TR, Heckbert SR, Budoff MJ, Van Rompaey S, Delaney JAC, Wong C, Tong W, Palella FJ, Elion RA, Martin JN, Brooks JT, Jacobson LP, Eron JJ, Justice AC, Freiberg MS, Klein DB, Post WS, Saag MS, Moore RD, Crane HM (2017) J Acquir Immune Defic Syndr 75(5): 568-576
    › Primary publication · 28520615 (PubMed) · PMC5522001 (PubMed Central)
  11. Isoniazid-monoresistant tuberculosis is associated with poor treatment outcomes in Durban, South Africa. van der Heijden YF, Karim F, Mufamadi G, Zako L, Chinappa T, Shepherd BE, Maruri F, Moosa MS, Sterling TR, Pym AS (2017) Int J Tuberc Lung Dis 21(6): 670-676
    › Primary publication · 28482962 (PubMed) · PMC5536436 (PubMed Central)
  12. Association of CD4+ T-cell Count, HIV-1 RNA Viral Load, and Antiretroviral Therapy With Kaposi Sarcoma Risk Among HIV-infected Persons in the United States and Canada. Dubrow R, Qin L, Lin H, Hernández-Ramírez RU, Neugebauer RS, Leyden W, Althoff KN, Achenbach CJ, Hessol NA, Modur SP, DʼSouza G, Bosch RJ, Grover S, Horberg MA, Kitahata MM, Mayor AM, Novak RM, Rabkin CS, Sterling TR, Goedert JJ, Justice AC, Engels EA, Moore RD, Silverberg MJ, North American AIDS Cohort Collaboration on Research and Design of the International Epidemiologic Databases to Evaluate AIDS (2017) J Acquir Immune Defic Syndr 75(4): 382-390
    › Primary publication · 28394855 (PubMed) · PMC5490794 (PubMed Central)
  13. Sex, Race, and HIV Risk Disparities in Discontinuity of HIV Care After Antiretroviral Therapy Initiation in the United States and Canada. Rebeiro PF, Abraham AG, Horberg MA, Althoff KN, Yehia BR, Buchacz K, Lau BM, Sterling TR, Gange SJ (2017) AIDS Patient Care STDS 31(3): 129-144
    › Primary publication · 28282246 (PubMed) · PMC5359655 (PubMed Central)
  14. Fluoroquinolones for the treatment and prevention of multidrug-resistant tuberculosis. Sterling TR (2016) Int J Tuberc Lung Dis 20(12): 42-47
    › Primary publication · 28240572 (PubMed)
  15. Tuberculosis and risk of acute myocardial infarction: a propensity score-matched analysis. Huaman MA, Kryscio RJ, Fichtenbaum CJ, Henson D, Salt E, Sterling TR, Garvy BA (2017) Epidemiol Infect 145(7): 1363-1367
    › Primary publication · 28202093 (PubMed) · PMC5616129 (PubMed Central)
  16. Factors associated with non-completion of follow-up: 33-month latent tuberculous infection treatment trial. Moro RN, Sterling TR, Saukkonen J, Vernon A, Horsburgh CR, Chaisson RE, Hamilton CD, Villarino ME, Goldberg S (2017) Int J Tuberc Lung Dis 21(3): 286-296
    › Primary publication · 28087928 (PubMed) · PMC6563818 (PubMed Central)
  17. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Lewinsohn DM, Leonard MK, LoBue PA, Cohn DL, Daley CL, Desmond E, Keane J, Lewinsohn DA, Loeffler AM, Mazurek GH, O'Brien RJ, Pai M, Richeldi L, Salfinger M, Shinnick TM, Sterling TR, Warshauer DM, Woods GL (2017) Clin Infect Dis 64(2): 111-115
    › Primary publication · 28052967 (PubMed) · PMC5504475 (PubMed Central)
  18. Pediatric multidrug-resistant tuberculosis clinical trials: challenges and opportunities. McAnaw SE, Hesseling AC, Seddon JA, Dooley KE, Garcia-Prats AJ, Kim S, Jenkins HE, Schaaf HS, Sterling TR, Horsburgh CR (2017) Int J Infect Dis : 194-199
    › Primary publication · 27955992 (PubMed) · PMC5606236 (PubMed Central)
  19. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Lewinsohn DM, Leonard MK, LoBue PA, Cohn DL, Daley CL, Desmond E, Keane J, Lewinsohn DA, Loeffler AM, Mazurek GH, O'Brien RJ, Pai M, Richeldi L, Salfinger M, Shinnick TM, Sterling TR, Warshauer DM, Woods GL (2017) Clin Infect Dis 64(2): e1-e33
    › Primary publication · 27932390 (PubMed)
  20. Tuberculosis and Cardiovascular Disease: Linking the Epidemics. Huaman MA, Henson D, Ticona E, Sterling TR, Garvy BA (2015) Trop Dis Travel Med Vaccines
    › Primary publication · 26835156 (PubMed) · PMC4729377 (PubMed Central)
  21. Geographic Variations in Retention in Care among HIV-Infected Adults in the United States. Rebeiro PF, Gange SJ, Horberg MA, Abraham AG, Napravnik S, Samji H, Yehia BR, Althoff KN, Moore RD, Kitahata MM, Sterling TR, Curriero FC, North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) (2016) PLoS One 11(1): e0146119
    › Primary publication · 26752637 (PubMed) · PMC4708981 (PubMed Central)
  22. Rifapentine Pharmacokinetics and Tolerability in Children and Adults Treated Once Weekly With Rifapentine and Isoniazid for Latent Tuberculosis Infection. Weiner M, Savic RM, Kenzie WR, Wing D, Peloquin CA, Engle M, Bliven E, Prihoda TJ, Gelfond JA, Scott NA, Abdel-Rahman SM, Kearns GL, Burman WJ, Sterling TR, Villarino ME, Tuberculosis Trials Consortium PREVENT TB Pharmacokinetic Group (2014) J Pediatric Infect Dis Soc 3(2): 132-45
    › Primary publication · 26625366 (PubMed)
  23. Laboratory Measures as Proxies for Primary Care Encounters: Implications for Quantifying Clinical Retention Among HIV-Infected Adults in North America. Rebeiro PF, Althoff KN, Lau B, Gill J, Abraham AG, Horberg MA, Kitahata MM, Yehia BR, Samji H, Brooks JT, Buchacz K, Napravnik S, Silverberg MJ, Rachlis A, Gebo KA, Sterling TR, Moore RD, Gange SJ, North American AIDS Cohort Collaboration on Research and Design (2015) Am J Epidemiol 182(11): 952-60
    › Primary publication · 26578717 (PubMed) · PMC4655744 (PubMed Central)
  24. Cumulative Incidence of Cancer Among Persons With HIV in North America: A Cohort Study. Silverberg MJ, Lau B, Achenbach CJ, Jing Y, Althoff KN, D'Souza G, Engels EA, Hessol NA, Brooks JT, Burchell AN, Gill MJ, Goedert JJ, Hogg R, Horberg MA, Kirk GD, Kitahata MM, Korthuis PT, Mathews WC, Mayor A, Modur SP, Napravnik S, Novak RM, Patel P, Rachlis AR, Sterling TR, Willig JH, Justice AC, Moore RD, Dubrow R, North American AIDS Cohort Collaboration on Research and Design of the International Epidemiologic Databases to Evaluate AIDS (2015) Ann Intern Med 163(7): 507-18
    › Primary publication · 26436616 (PubMed) · PMC4711936 (PubMed Central)
  25. The metabolic and cardiovascular consequences of obesity in persons with HIV on long-term antiretroviral therapy. Koethe JR, Grome H, Jenkins CA, Kalams SA, Sterling TR (2016) AIDS 30(1): 83-91
    › Primary publication · 26418084 (PubMed) · PMC4703444 (PubMed Central)
  26. RePORT International: Advancing Tuberculosis Biomarker Research Through Global Collaboration. Hamilton CD, Swaminathan S, Christopher DJ, Ellner J, Gupta A, Sterling TR, Rolla V, Srinivasan S, Karyana M, Siddiqui S, Stoszek SK, Kim P (2015) Clin Infect Dis : S155-9
    › Primary publication · 26409277 (PubMed) · PMC4583572 (PubMed Central)
  27. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Getahun H, Matteelli A, Abubakar I, Aziz MA, Baddeley A, Barreira D, Den Boon S, Borroto Gutierrez SM, Bruchfeld J, Burhan E, Cavalcante S, Cedillos R, Chaisson R, Chee CB, Chesire L, Corbett E, Dara M, Denholm J, de Vries G, Falzon D, Ford N, Gale-Rowe M, Gilpin C, Girardi E, Go UY, Govindasamy D, D Grant A, Grzemska M, Harris R, Horsburgh CR, Ismayilov A, Jaramillo E, Kik S, Kranzer K, Lienhardt C, LoBue P, Lönnroth K, Marks G, Menzies D, Migliori GB, Mosca D, Mukadi YD, Mwinga A, Nelson L, Nishikiori N, Oordt-Speets A, Rangaka MX, Reis A, Rotz L, Sandgren A, Sañé Schepisi M, Schünemann HJ, Sharma SK, Sotgiu G, Stagg HR, Sterling TR, Tayeb T, Uplekar M, van der Werf MJ, Vandevelde W, van Kessel F, van't Hoog A, Varma JK, Vezhnina N, Voniatis C, Vonk Noordegraaf-Schouten M, Weil D, Weyer K, Wilkinson RJ, Yoshiyama T, Zellweger JP, Raviglione M (2015) Eur Respir J 46(6): 1563-76
    › Primary publication · 26405286 (PubMed) · PMC4664608 (PubMed Central)
  28. Rising Obesity Prevalence and Weight Gain Among Adults Starting Antiretroviral Therapy in the United States and Canada. Koethe JR, Jenkins CA, Lau B, Shepherd BE, Justice AC, Tate JP, Buchacz K, Napravnik S, Mayor AM, Horberg MA, Blashill AJ, Willig A, Wester CW, Silverberg MJ, Gill J, Thorne JE, Klein M, Eron JJ, Kitahata MM, Sterling TR, Moore RD, North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) (2016) AIDS Res Hum Retroviruses 32(1): 50-8
    › Primary publication · 26352511 (PubMed) · PMC4692122 (PubMed Central)
  29. Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI. Bliven-Sizemore EE, Sterling TR, Shang N, Benator D, Schwartzman K, Reves R, Drobeniuc J, Bock N, Villarino ME, TB Trials Consortium (2015) Int J Tuberc Lung Dis 19(9): 1039-44, i-v
    › Primary publication · 26260821 (PubMed) · PMC5080618 (PubMed Central)
  30. Body mass index and early CD4 T-cell recovery among adults initiating antiretroviral therapy in North America, 1998-2010. Koethe JR, Jenkins CA, Lau B, Shepherd BE, Silverberg MJ, Brown TT, Blashill AJ, Anema A, Willig A, Stinnette S, Napravnik S, Gill J, Crane HM, Sterling TR, North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) (2015) HIV Med 16(9): 572-7
    › Primary publication · 25960080 (PubMed) · PMC4558259 (PubMed Central)
  31. Four-month fluoroquinolone-containing regimens are inferior to standard 6-month tuberculosis treatment. Sterling TR (2015) Evid Based Med 20(4): 128-9
    › Primary publication · 25926523 (PubMed)
  32. Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study. Sterling TR, Moro RN, Borisov AS, Phillips E, Shepherd G, Adkinson NF, Weis S, Ho C, Villarino ME, Tuberculosis Trials Consortium (2015) Clin Infect Dis 61(4): 527-35
    › Primary publication · 25904367 (PubMed) · PMC4560029 (PubMed Central)
  33. Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals: The Antiretroviral Therapy Cohort Collaboration. May MT, Justice AC, Birnie K, Ingle SM, Smit C, Smith C, Neau D, Guiguet M, Schwarze-Zander C, Moreno S, Guest JL, Monforte Ad, Tural C, Gill MJ, Bregenzer A, Kirk O, Saag M, Sterling TR, Crane HM, Sterne JA (2015) J Acquir Immune Defic Syndr 69(3): 348-54
    › Primary publication · 25848927 (PubMed) · PMC4506784 (PubMed Central)
  34. Hormonal Contraception and Risk of Psychiatric and Other Noncommunicable Diseases in HIV-Infected Women. Castilho JL, Jenkins CA, Shepherd BE, Bebawy SS, Turner M, Sterling TR, Melekhin VV (2015) J Womens Health (Larchmt) 24(6): 481-8
    › Primary publication · 25751720 (PubMed) · PMC4490777 (PubMed Central)
  35. HIV and cancer: a comparative retrospective study of Brazilian and U.S. clinical cohorts. Castilho JL, Luz PM, Shepherd BE, Turner M, Ribeiro SR, Bebawy SS, Netto JS, McGowan CC, Veloso VG, Engels EA, Sterling TR, Grinsztejn B (2015) Infect Agent Cancer : 4
    › Primary publication · 25685180 (PubMed) · PMC4327947 (PubMed Central)
  36. Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid. Villarino ME, Scott NA, Weis SE, Weiner M, Conde MB, Jones B, Nachman S, Oliveira R, Moro RN, Shang N, Goldberg SV, Sterling TR, International Maternal Pediatric and Adolescents AIDS Clinical Trials Group, Tuberculosis Trials Consortium (2015) JAMA Pediatr 169(3): 247-55
    › Primary publication · 25580725 (PubMed) · PMC6624831 (PubMed Central)
  37. A comparison of interview methods to ascertain fluoroquinolone exposure before tuberculosis diagnosis. Van Der Heijden YF, Maruri F, Holt E, Mitchel E, Warkentin J, Sterling TR (2015) Epidemiol Infect 143(5): 960-5
    › Primary publication · 25420688 (PubMed) · PMC4352378 (PubMed Central)
  38. Detection and management of drug-resistant tuberculosis in HIV-infected patients in lower-income countries. Ballif M, Nhandu V, Wood R, Dusingize JC, Carter EJ, Cortes CP, McGowan CC, Diero L, Graber C, Renner L, Hawerlander D, Kiertiburanakul S, Du QT, Sterling TR, Egger M, Fenner L, International epidemiological Databases to Evaluate AIDS (IeDEA) (2014) Int J Tuberc Lung Dis 18(11): 1327-36
    › Primary publication · 25299866 (PubMed) · PMC4323497 (PubMed Central)
  39. Diagnosis and treatment of latent tuberculosis infection: an update. Person AK, Pettit AC, Sterling TR (2013) Curr Respir Care Rep 2(4): 199-207
    › Primary publication · 25298921 (PubMed) · PMC4185413 (PubMed Central)
  40. Current drug use and lack of HIV virologic suppression: point-of-care urine drug screen versus self-report. Qian HZ, Mitchell VJ, Bebawy S, Cassell H, Perez G, McGowan CC, Sterling TR, Vermund SH, D'Aquila R, Hulgan T (2014) BMC Infect Dis : 508
    › Primary publication · 25234368 (PubMed) · PMC4175271 (PubMed Central)
  41. Body mass index and the risk of incident noncommunicable diseases after starting antiretroviral therapy. Koethe JR, Jenkins CA, Turner M, Bebawy S, Shepherd BE, Wester CW, Sterling TR (2015) HIV Med 16(1): 67-72
    › Primary publication · 25230709 (PubMed) · PMC4268383 (PubMed Central)
  42. Tuberculosis and the risk of infection with other intracellular bacteria: a population-based study. Huaman MA, Fiske CT, Jones TF, Warkentin J, Shepherd BE, Ingram LA, Maruri F, Sterling TR (2015) Epidemiol Infect 143(5): 951-9
    › Primary publication · 25148655 (PubMed) · PMC4336842 (PubMed Central)
  43. Treatment of Mycobacterium tuberculosis infection: time to get a move on? Menzies D, Sterling TR (2014) Ann Intern Med 161(6): 449-50
    › Primary publication · 25111391 (PubMed)
  44. Impact of risk factors for specific causes of death in the first and subsequent years of antiretroviral therapy among HIV-infected patients. Ingle SM, May MT, Gill MJ, Mugavero MJ, Lewden C, Abgrall S, Fätkenheuer G, Reiss P, Saag MS, Manzardo C, Grabar S, Bruyand M, Moore D, Mocroft A, Sterling TR, D'Arminio Monforte A, Hernando V, Teira R, Guest J, Cavassini M, Crane HM, Sterne JA, Antiretroviral Therapy Cohort Collaboration (2014) Clin Infect Dis 59(2): 287-97
    › Primary publication · 24771333 (PubMed) · PMC4073781 (PubMed Central)
  45. High proportion of heteroresistance in gyrA and gyrB in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates. Eilertson B, Maruri F, Blackman A, Herrera M, Samuels DC, Sterling TR (2014) Antimicrob Agents Chemother 58(6): 3270-5
    › Primary publication · 24687490 (PubMed) · PMC4068501 (PubMed Central)
  46. Risk factors for treatment default in close contacts with latent tuberculous infection. Fiske CT, Yan FX, Hirsch-Moverman Y, Sterling TR, Reichler MR, Tuberculosis Epidemiologic Studies Consortium Task Order 2 Team (2014) Int J Tuberc Lung Dis 18(4): 421-7
    › Primary publication · 24670696 (PubMed) · PMC4060979 (PubMed Central)
  47. Disparities in the quality of HIV care when using US Department of Health and Human Services indicators. Althoff KN, Rebeiro P, Brooks JT, Buchacz K, Gebo K, Martin J, Hogg R, Thorne JE, Klein M, Gill MJ, Sterling TR, Yehia B, Silverberg MJ, Crane H, Justice AC, Gange SJ, Moore R, Kitahata MM, Horberg MA, North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) (2014) Clin Infect Dis 58(8): 1185-9
    › Primary publication · 24463281 (PubMed) · PMC3967825 (PubMed Central)
  48. Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery. Engsig FN, Zangerle R, Katsarou O, Dabis F, Reiss P, Gill J, Porter K, Sabin C, Riordan A, Fätkenheuer G, Gutiérrez F, Raffi F, Kirk O, Mary-Krause M, Stephan C, de Olalla PG, Guest J, Samji H, Castagna A, d'Arminio Monforte A, Skaletz-Rorowski A, Ramos J, Lapadula G, Mussini C, Force L, Meyer L, Lampe F, Boufassa F, Bucher HC, De Wit S, Burkholder GA, Teira R, Justice AC, Sterling TR, M Crane H, Gerstoft J, Grarup J, May M, Chêne G, Ingle SM, Sterne J, Obel N, Antiretroviral Therapy Cohort Collaboration (ART-CC) and the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord (2014) Clin Infect Dis 58(9): 1312-21
    › Primary publication · 24457342 (PubMed) · PMC6276895 (PubMed Central)
  49. Sex differences in HIV outcomes in the highly active antiretroviral therapy era: a systematic review. Castilho JL, Melekhin VV, Sterling TR (2014) AIDS Res Hum Retroviruses 30(5): 446-56
    › Primary publication · 24401107 (PubMed) · PMC4010172 (PubMed Central)
  50. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. Samji H, Cescon A, Hogg RS, Modur SP, Althoff KN, Buchacz K, Burchell AN, Cohen M, Gebo KA, Gill MJ, Justice A, Kirk G, Klein MB, Korthuis PT, Martin J, Napravnik S, Rourke SB, Sterling TR, Silverberg MJ, Deeks S, Jacobson LP, Bosch RJ, Kitahata MM, Goedert JJ, Moore R, Gange SJ, North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA (2013) PLoS One 8(12): e81355
    › Primary publication · 24367482 (PubMed) · PMC3867319 (PubMed Central)
  51. 25-Hydroxyvitamin D levels after recovery from tuberculosis: insights into pathogenesis. Huaman MA, Sterling TR, Shepherd BE, Fiske CT (2014) Tuberculosis (Edinb) 94(1): 51-4
    › Primary publication · 24275362 (PubMed) · PMC3938285 (PubMed Central)
  52. Association between U.S. state AIDS Drug Assistance Program (ADAP) features and HIV antiretroviral therapy initiation, 2001-2009. Hanna DB, Buchacz K, Gebo KA, Hessol NA, Horberg MA, Jacobson LP, Kirk GD, Kitahata MM, Korthuis PT, Moore RD, Napravnik S, Patel P, Silverberg MJ, Sterling TR, Willig JH, Collier A, Samji H, Thorne JE, Althoff KN, Martin JN, Rodriguez B, Stuart EA, Gange SJ, North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the International Epidemiologic Databases to Evaluate AIDS (IeDEA) (2013) PLoS One 8(11): e78952
    › Primary publication · 24260137 (PubMed) · PMC3832515 (PubMed Central)
  53. Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States. Shepardson D, Marks SM, Chesson H, Kerrigan A, Holland DP, Scott N, Tian X, Borisov AS, Shang N, Heilig CM, Sterling TR, Villarino ME, Mac Kenzie WR (2013) Int J Tuberc Lung Dis 17(12): 1531-7
    › Primary publication · 24200264 (PubMed) · PMC5451112 (PubMed Central)
  54. Tuberculosis in antiretroviral treatment programs in lower income countries: availability and use of diagnostics and screening. Fenner L, Ballif M, Graber C, Nhandu V, Dusingize JC, Cortes CP, Carriquiry G, Anastos K, Garone D, Jong E, Gnokoro JC, Sued O, Ajayi S, Diero L, Wools-Kaloustian K, Kiertiburanakul S, Castelnuovo B, Lewden C, Durier N, Sterling TR, Egger M, International epidemiological Databases to Evaluate AIDS (IeDEA) (2013) PLoS One 8(10): e77697
    › Primary publication · 24147059 (PubMed) · PMC3798412 (PubMed Central)
  55. Duration of anti-tuberculosis therapy and timing of antiretroviral therapy initiation: association with mortality in HIV-related tuberculosis. Cortes CP, Wehbe FH, McGowan CC, Shepherd BE, Duda SN, Jenkins CA, Gonzalez E, Carriquiry G, Schechter M, Padgett D, Cesar C, Madero JS, Pape JW, Masys DR, Sterling TR, Caribbean, Central American, South American Network for HIV Research of the International Epidemiologic Databases to Evaluate AIDS (2013) PLoS One 8(9): e74057
    › Primary publication · 24066096 (PubMed) · PMC3774609 (PubMed Central)
  56. Higher rates of AIDS during the first year of antiretroviral therapy among migrants: the importance of tuberculosis. Antiretroviral Therapy Cohort Collaboration (ART-CC), Shepherd BE, Jenkins CA, Parrish DD, Glass TR, Cescon A, Masabeu A, Chene G, de Wolf F, Crane HM, Jarrin I, Gill J, del Amo J, Abgrall S, Khaykin P, Lehmann C, Ingle SM, May MT, Sterne JA, Sterling TR (2013) AIDS 27(8): 1321-9
    › Primary publication · 23925379 (PubMed) · PMC3992322 (PubMed Central)
  57. Hepatitis C viremia and the risk of chronic kidney disease in HIV-infected individuals. Lucas GM, Jing Y, Sulkowski M, Abraham AG, Estrella MM, Atta MG, Fine DM, Klein MB, Silverberg MJ, Gill MJ, Moore RD, Gebo KA, Sterling TR, Butt AA, NA-ACCORD of the IeDEA (2013) J Infect Dis 208(8): 1240-9
    › Primary publication · 23904290 (PubMed) · PMC3778973 (PubMed Central)
  58. Female sex and discontinuation of isoniazid due to adverse effects during the treatment of latent tuberculosis. Pettit AC, Bethel J, Hirsch-Moverman Y, Colson PW, Sterling TR, Tuberculosis Epidemiologic Studies Consortium (2013) J Infect 67(5): 424-32
    › Primary publication · 23845828 (PubMed) · PMC3788833 (PubMed Central)
  59. Fluoroquinolone susceptibility in Mycobacterium tuberculosis after pre-diagnosis exposure to older- versus newer-generation fluoroquinolones. van der Heijden YF, Maruri F, Blackman A, Mitchel E, Bian A, Shintani AK, Eden S, Warkentin JV, Sterling TR (2013) Int J Antimicrob Agents 42(3): 232-7
    › Primary publication · 23806638 (PubMed) · PMC3780576 (PubMed Central)
  60. Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009. Abgrall S, Ingle SM, May MT, Costagliola D, Mercie P, Cavassini M, Reekie J, Samji H, Gill MJ, Crane HM, Tate J, Sterling TR, Antinori A, Reiss P, Saag MS, Mugavero MJ, Phillips A, Manzardo C, Wasmuth JC, Stephan C, Guest JL, Gomez Sirvent JL, Sterne JA, Antiretroviral Therapy Cohort Collaboration (ART-CC) (2013) AIDS 27(5): 803-13
    › Primary publication · 23719350 (PubMed)
  61. Are we ready to shorten the treatment duration for non-cavitary pulmonary tuberculosis? Chang KC, Sterling TR, Yew WW (2013) Int J Tuberc Lung Dis 17(6): 712
    › Primary publication · 23676152 (PubMed)
  62. Cohort profile: Antiretroviral Therapy Cohort Collaboration (ART-CC). May MT, Ingle SM, Costagliola D, Justice AC, de Wolf F, Cavassini M, D'Arminio Monforte A, Casabona J, Hogg RS, Mocroft A, Lampe FC, Dabis F, Fätkenheuer G, Sterling TR, del Amo J, Gill MJ, Crane HM, Saag MS, Guest J, Brodt HR, Sterne JA, Antiretroviral Cohort Collaboration (2014) Int J Epidemiol 43(3): 691-702
    › Primary publication · 23599235 (PubMed) · PMC4052127 (PubMed Central)
  63. Circulating interleukin-6, soluble CD14, and other inflammation biomarker levels differ between obese and nonobese HIV-infected adults on antiretroviral therapy. Koethe JR, Dee K, Bian A, Shintani A, Turner M, Bebawy S, Sterling TR, Hulgan T (2013) AIDS Res Hum Retroviruses 29(7): 1019-25
    › Primary publication · 23469772 (PubMed) · PMC3685684 (PubMed Central)
  64. Non-adherence and drug-related interruptions are risk factors for delays in completion of treatment for tuberculosis. Pettit AC, Cummins J, Kaltenbach LA, Sterling TR, Warkentin JV (2013) Int J Tuberc Lung Dis 17(4): 486-92
    › Primary publication · 23394818 (PubMed) · PMC3981539 (PubMed Central)
  65. Trends and disparities in antiretroviral therapy initiation and virologic suppression among newly treatment-eligible HIV-infected individuals in North America, 2001-2009. Hanna DB, Buchacz K, Gebo KA, Hessol NA, Horberg MA, Jacobson LP, Kirk GD, Kitahata MM, Korthuis PT, Moore RD, Napravnik S, Patel P, Silverberg MJ, Sterling TR, Willig JH, Lau B, Althoff KN, Crane HM, Collier AC, Samji H, Thorne JE, Gill MJ, Klein MB, Martin JN, Rodriguez B, Rourke SB, Gange SJ, North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the International Epidemiologic Databases to Evaluate AIDS (2013) Clin Infect Dis 56(8): 1174-82
    › Primary publication · 23315317 (PubMed) · PMC3657490 (PubMed Central)
  66. Virologic, immunologic and clinical responses in foreign-born versus US-born HIV-1 infected adults initiating antiretroviral therapy: an observational cohort study. Parrish DD, Blevins M, Stinnette SE, Rebeiro PF, Shepherd BE, Sterling TR, McGowan CC, Wester CW (2012) PLoS One 7(12): e52336
    › Primary publication · 23284994 (PubMed) · PMC3526482 (PubMed Central)
  67. Chronic kidney disease at presentation is not an independent risk factor for AIDS-defining events or death in HIV-infected persons. Alves TP, Wu P, Ikizler TA, Sterling TR, Stinnette SE, Rebeiro PF, Ghosh S, Hulgan T (2013) Clin Nephrol 79(2): 93-100
    › Primary publication · 23270930 (PubMed) · PMC3726221 (PubMed Central)
  68. Invasive cervical cancer risk among HIV-infected women: a North American multicohort collaboration prospective study. Abraham AG, D'Souza G, Jing Y, Gange SJ, Sterling TR, Silverberg MJ, Saag MS, Rourke SB, Rachlis A, Napravnik S, Moore RD, Klein MB, Kitahata MM, Kirk GD, Hogg RS, Hessol NA, Goedert JJ, Gill MJ, Gebo KA, Eron JJ, Engels EA, Dubrow R, Crane HM, Brooks JT, Bosch RJ, Strickler HD, North American AIDS Cohort Collaboration on Research and Design of IeDEA (2013) J Acquir Immune Defic Syndr 62(4): 405-13
    › Primary publication · 23254153 (PubMed) · PMC3633634 (PubMed Central)
  69. Retention among North American HIV-infected persons in clinical care, 2000-2008. Rebeiro P, Althoff KN, Buchacz K, Gill J, Horberg M, Krentz H, Moore R, Sterling TR, Brooks JT, Gebo KA, Hogg R, Klein M, Martin J, Mugavero M, Rourke S, Silverberg MJ, Thorne J, Gange SJ, North American AIDS Cohort Collaboration on Research and Design (2013) J Acquir Immune Defic Syndr 62(3): 356-62
    › Primary publication · 23242158 (PubMed) · PMC3661708 (PubMed Central)
  70. Predictive accuracy of the Veterans Aging Cohort Study index for mortality with HIV infection: a North American cross cohort analysis. Justice AC, Modur SP, Tate JP, Althoff KN, Jacobson LP, Gebo KA, Kitahata MM, Horberg MA, Brooks JT, Buchacz K, Rourke SB, Rachlis A, Napravnik S, Eron J, Willig JH, Moore R, Kirk GD, Bosch R, Rodriguez B, Hogg RS, Thorne J, Goedert JJ, Klein M, Gill J, Deeks S, Sterling TR, Anastos K, Gange SJ, NA-ACCORD and VACS Project Teams (2013) J Acquir Immune Defic Syndr 62(2): 149-63
    › Primary publication · 23187941 (PubMed) · PMC3619393 (PubMed Central)
  71. An internationally generalizable risk index for mortality after one year of antiretroviral therapy. Tate JP, Justice AC, Hughes MD, Bonnet F, Reiss P, Mocroft A, Nattermann J, Lampe FC, Bucher HC, Sterling TR, Crane HM, Kitahata MM, May M, Sterne JA (2013) AIDS 27(4): 563-72
    › Primary publication · 23095314 (PubMed) · PMC4283204 (PubMed Central)
  72. Outcomes of second combination antiretroviral therapy regimens among HIV-infected persons in clinical care: a multicenter cohort study. Napravnik S, Eron JJ, Sterling TR, Juday T, Uy J, Moore RD (2013) AIDS Res Hum Retroviruses 29(3): 574-80
    › Primary publication · 23072322 (PubMed) · PMC3581035 (PubMed Central)
  73. Hemoglobin may contribute to sex differences in mortality among HIV-infected persons in care. Melekhin VV, Shepherd BE, Stinnette SE, Rebeiro PF, Turner MM, Sterling TR (2012) PLoS One 7(9): e44999
    › Primary publication · 23028732 (PubMed) · PMC3441736 (PubMed Central)
  74. U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008. Althoff KN, Buchacz K, Hall HI, Zhang J, Hanna DB, Rebeiro P, Gange SJ, Moore RD, Kitahata MM, Gebo KA, Martin J, Justice AC, Horberg MA, Hogg RS, Sterling TR, Cescon A, Klein MB, Thorne JE, Crane HM, Mugavero MJ, Napravnik S, Kirk GD, Jacobson LP, Brooks JT, North American AIDS Cohort Collaboration on Research and Design (2012) Ann Intern Med 157(5): 325-35
    › Primary publication · 22944874 (PubMed) · PMC3534765 (PubMed Central)
  75. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. Suthar AB, Lawn SD, del Amo J, Getahun H, Dye C, Sculier D, Sterling TR, Chaisson RE, Williams BG, Harries AD, Granich RM (2012) PLoS Med 9(7): e1001270
    › Primary publication · 22911011 (PubMed) · PMC3404110 (PubMed Central)
  76. Fluoroquinolone exposure prior to tuberculosis diagnosis is associated with an increased risk of death. van der Heijden YF, Maruri F, Blackman A, Holt E, Warkentin JV, Shepherd BE, Sterling TR (2012) Int J Tuberc Lung Dis 16(9): 1162-7
    › Primary publication · 22794509 (PubMed) · PMC3981533 (PubMed Central)
  77. Abnormal immune responses in persons with previous extrapulmonary tuberculosis in an in vitro model that simulates in vivo infection with Mycobacterium tuberculosis. Fiske CT, de Almeida AS, Shintani AK, Kalams SA, Sterling TR (2012) Clin Vaccine Immunol 19(8): 1142-9
    › Primary publication · 22675156 (PubMed) · PMC3416084 (PubMed Central)
  78. Active cocaine use is associated with lack of HIV-1 virologic suppression independent of nonadherence to antiretroviral therapy: use of a rapid screening tool during routine clinic visits. Rasbach DA, Desruisseau AJ, Kipp AM, Stinnette S, Kheshti A, Shepherd BE, Sterling TR, Hulgan T, McGowan CC, Qian HZ (2013) AIDS Care 25(1): 109-17
    › Primary publication · 22670566 (PubMed) · PMC3443534 (PubMed Central)
  79. Treatment of latent tuberculosis infection in HIV: shorter or longer? Person AK, Sterling TR (2012) Curr HIV/AIDS Rep 9(3): 259-66
    › Primary publication · 22581360 (PubMed) · PMC3410968 (PubMed Central)
  80. Accuracy of pharmacy and coded-diagnosis information in identifying tuberculosis in patients with rheumatoid arthritis. Fiske CT, Griffin MR, Mitchel E, Sterling TR, Grijalva CG (2012) Pharmacoepidemiol Drug Saf 21(6): 666-9
    › Primary publication · 22532509 (PubMed) · PMC3371104 (PubMed Central)
  81. Abnormal spontaneous interleukin 8 receptor expression: a brief report of two cases. Antas P, Holland S, Sterling T (2012) Rev Soc Bras Med Trop 45(1): 134-7
    › Primary publication · 22370847 (PubMed) · PMC3981535 (PubMed Central)
  82. Microcolonies in fluoroquinolone agar proportion susceptibility testing of Mycobacterium tuberculosis: an indicator of drug resistance. Blackman A, May S, Devasia RA, Maruri F, Stratton C, Sterling TR (2012) Eur J Clin Microbiol Infect Dis 31(9): 2177-82
    › Primary publication · 22322359 (PubMed) · PMC3981548 (PubMed Central)
  83. Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Silverberg MJ, Lau B, Justice AC, Engels E, Gill MJ, Goedert JJ, Kirk GD, D'Souza G, Bosch RJ, Brooks JT, Napravnik S, Hessol NA, Jacobson LP, Kitahata MM, Klein MB, Moore RD, Rodriguez B, Rourke SB, Saag MS, Sterling TR, Gebo KA, Press N, Martin JN, Dubrow R, North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA (2012) Clin Infect Dis 54(7): 1026-34
    › Primary publication · 22291097 (PubMed) · PMC3297645 (PubMed Central)
  84. A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. Maruri F, Sterling TR, Kaiga AW, Blackman A, van der Heijden YF, Mayer C, Cambau E, Aubry A (2012) J Antimicrob Chemother 67(4): 819-31
    › Primary publication · 22279180 (PubMed) · PMC3299416 (PubMed Central)
  85. High proportion of fluoroquinolone-resistant Mycobacterium tuberculosis isolates with novel gyrase polymorphisms and a gyrA region associated with fluoroquinolone susceptibility. Devasia R, Blackman A, Eden S, Li H, Maruri F, Shintani A, Alexander C, Kaiga A, Stratton CW, Warkentin J, Tang YW, Sterling TR (2012) J Clin Microbiol 50(4): 1390-6
    › Primary publication · 22189117 (PubMed) · PMC3318526 (PubMed Central)
  86. Three months of rifapentine and isoniazid for latent tuberculosis infection. Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, Hackman J, Hamilton CD, Menzies D, Kerrigan A, Weis SE, Weiner M, Wing D, Conde MB, Bozeman L, Horsburgh CR, Chaisson RE, TB Trials Consortium PREVENT TB Study Team (2011) N Engl J Med 365(23): 2155-66
    › Primary publication · 22150035 (PubMed)
  87. Increased frequency of regulatory T cells and T lymphocyte activation in persons with previously treated extrapulmonary tuberculosis. de Almeida AS, Fiske CT, Sterling TR, Kalams SA (2012) Clin Vaccine Immunol 19(1): 45-52
    › Primary publication · 22038848 (PubMed) · PMC3255960 (PubMed Central)
  88. An optimal body mass index range associated with improved immune reconstitution among HIV-infected adults initiating antiretroviral therapy. Koethe JR, Jenkins CA, Shepherd BE, Stinnette SE, Sterling TR (2011) Clin Infect Dis 53(9): 952-60
    › Primary publication · 21946189 (PubMed) · PMC3189168 (PubMed Central)
  89. Risk factors for tuberculosis after highly active antiretroviral therapy initiation in the United States and Canada: implications for tuberculosis screening. Sterling TR, Lau B, Zhang J, Freeman A, Bosch RJ, Brooks JT, Deeks SG, French A, Gange S, Gebo KA, John Gill M, Horberg MA, Jacobson LP, Kirk GD, Kitahata MM, Klein MB, Martin JN, Rodriguez B, Silverberg MJ, Willig JH, Eron JJ, Goedert JJ, Hogg RS, Justice AC, McKaig RG, Napravnik S, Thorne J, Moore RD, North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the International Epidemiologic Databases to Evaluate AIDS (IeDEA) (2011) J Infect Dis 204(6): 893-901
    › Primary publication · 21849286 (PubMed) · PMC3156918 (PubMed Central)
  90. Missing data on the estimation of the prevalence of accumulated human immunodeficiency virus drug resistance in patients treated with antiretroviral drugs in north america. Abraham AG, Lau B, Deeks S, Moore RD, Zhang J, Eron J, Harrigan R, Gill MJ, Kitahata M, Klein M, Napravnik S, Rachlis A, Rodriguez B, Rourke S, Benson C, Bosch R, Collier A, Gebo K, Goedert J, Hogg R, Horberg M, Jacobson L, Justice A, Kirk G, Martin J, McKaig R, Silverberg M, Sterling T, Thorne J, Willig J, Gange SJ, North American AIDS Cohort Collaboration on Research and Design of the International Epidemiologic Databases to Evaluate AIDS (2011) Am J Epidemiol 174(6): 727-35
    › Primary publication · 21813792 (PubMed) · PMC3202147 (PubMed Central)
  91. Chronic lung disease and HIV infection are risk factors for recurrent tuberculosis in a low-incidence setting. Pettit AC, Kaltenbach LA, Maruri F, Cummins J, Smith TR, Warkentin JV, Griffin MR, Sterling TR (2011) Int J Tuberc Lung Dis 15(7): 906-11
    › Primary publication · 21682963 (PubMed) · PMC3172045 (PubMed Central)
  92. Non-AIDS-defining events among HIV-1-infected adults receiving combination antiretroviral therapy in resource-replete versus resource-limited urban setting. Wester CW, Koethe JR, Shepherd BE, Stinnette SE, Rebeiro PF, Kipp AM, Hong H, Bussmann H, Gaolathe T, McGowan CC, Sterling TR, Marlink RG (2011) AIDS 25(12): 1471-9
    › Primary publication · 21572309 (PubMed) · PMC3188442 (PubMed Central)
  93. Drug use and receipt of highly active antiretroviral therapy among HIV-infected persons in two U.S. clinic cohorts. McGowan CC, Weinstein DD, Samenow CP, Stinnette SE, Barkanic G, Rebeiro PF, Sterling TR, Moore RD, Hulgan T (2011) PLoS One 6(4): e18462
    › Primary publication · 21541016 (PubMed) · PMC3081810 (PubMed Central)
  94. Tuberculosis risk before and after highly active antiretroviral therapy initiation: does HAART increase the short-term TB risk in a low incidence TB setting? Pettit AC, Jenkins CA, Stinnette SE, Rebeiro PF, Blackwell RB, Raffanti SP, Shepherd BE, Sterling TR (2011) J Acquir Immune Defic Syndr 57(4): 305-10
    › Primary publication · 21423024 (PubMed) · PMC3141096 (PubMed Central)
  95. The relationship between injection and noninjection drug use and HIV disease progression. Qian HZ, Stinnette SE, Rebeiro PF, Kipp AM, Shepherd BE, Samenow CP, Jenkins CA, No P, McGowan CC, Hulgan T, Sterling TR (2011) J Subst Abuse Treat 41(1): 14-20
    › Primary publication · 21349679 (PubMed) · PMC3110534 (PubMed Central)
  96. Novel human genetic variants associated with extrapulmonary tuberculosis: a pilot genome wide association study. Oki NO, Motsinger-Reif AA, Antas PR, Levy S, Holland SM, Sterling TR (2011) BMC Res Notes : 28
    › Primary publication · 21281516 (PubMed) · PMC3041678 (PubMed Central)
  97. CD4 count at presentation for HIV care in the United States and Canada: are those over 50 years more likely to have a delayed presentation? Althoff KN, Gebo KA, Gange SJ, Klein MB, Brooks JT, Hogg RS, Bosch RJ, Horberg MA, Saag MS, Kitahata MM, Eron JJ, Napravnik S, Rourke SB, Gill MJ, Rodriguez B, Sterling TR, Deeks SG, Martin JN, Jacobson LP, Kirk GD, Collier AC, Benson CA, Silverberg MJ, Goedert JJ, McKaig RG, Thorne J, Rachlis A, Moore RD, Justice AC, North American AIDS Cohort Collaboration on Research and Design (2010) AIDS Res Ther : 45
    › Primary publication · 21159161 (PubMed) · PMC3022663 (PubMed Central)
  98. Race, kidney disease progression, and mortality risk in HIV-infected persons. Alves TP, Hulgan T, Wu P, Sterling TR, Stinnette SE, Rebeiro PF, Vincz AJ, Bruce M, Ikizler TA (2010) Clin J Am Soc Nephrol 5(12): 2269-75
    › Primary publication · 20876679 (PubMed) · PMC2994089 (PubMed Central)